Autopsy report · NCT07255846

A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

“This decision is based solely on internal company prioritization and resource allocation considerations. No patients have been enrolled or dosed in this study and no clinical data have been generated.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Terremoto Biosciences Inc.

Sponsor type

Industry

Conditions

Hereditary Hemorrhagic Telangiectasia (HHT)

Interventions

TER-1754; Placebo; TER-1754

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR
  “This is an internal decision based on prioritisations and no safety issues have been raised during the trial.” (58% match in meaning)
• Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
  “The study has been terminated due to a change in internal prioritization and not due to any safety concerns.” (58% match in meaning)
• Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
  “The primary objective has already been answered with the number of recruited patients.” (57% match in meaning)
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack
  “In view of the continuing insufficient patient recruitment in the study due to the difficult epidemiological situation and the need for rational allocation of company resources, as well as based on the results of the interim analysis.” (56% match in meaning)
• Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix®
  “This study has been cancelled before initiation due to company's prioritisation decisions linked to resources restrictions.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.